Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Halozyme Therapeutics announces initiation of rivipansel Phase 1 clinical trial

Halozyme Therapeutics, Inc. today announced that the first healthy subject has been dosed in a Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of a subcutaneous formulation of rivipansel, a compound discovered by GlycoMimetics, Inc. and being developed by Pfizer Inc., using Halozyme's ENHANZE formulation.

30 Oct 2015

UNM CCC biostatisticians help scientists conduct research on cancer

In contrast to most people, Ji-Hyun Lee, DrPH, doesn't find statistics difficult or boring. For her, statistics is fulfilling because it's how she helps people fight cancer. "People think biostatistics is purely numbers," Lee says, "but my work helps to improve patients' care." She recalls a visit to a hospital patient as a young statistician working for a cystic fibrosis research team.

29 Oct 2015

Breastfeeding associated with lower risk of developing hormone-receptor negative breast cancer

A large international study shows that breastfeeding is associated with a lower risk of developing an aggressive form of breast cancer called hormone-receptor negative. This new combined evidence shows the risk was reduced by up to 20% in women who breastfed.

29 Oct 2015

Franziska Michor named recipient of NYSCF - Robertson Stem Cell Prize

The New York Stem Cell Foundation announced today that Franziska Michor, PhD, is the 2015 recipient of the NYSCF - Robertson Stem Cell Prize for her work pioneering new approaches to study the growth, spread, and treatment of cancer. Her laboratory fuses her passions in mathematics, molecular biology and patient care to investigate how cancers form and progress.

29 Oct 2015

Oncolytic (cancer-killing) viral therapy approved in the U.S. for use against late-stage melanoma

The U.S. Food and Drug Administration announced on Oct. 27 that it has approved, for the first time, an oncolytic (cancer-killing) viral therapy in the United States. The drug was approved for use against late-stage melanoma, a deadly skin cancer that can be difficult to treat.

29 Oct 2015

Yervoy approved for patients at high risk of developing recurrence of melanoma after surgery

Today the U.S. Food and Drug Administration expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma, to lower the risk that the melanoma will return following surgery.

29 Oct 2015

IMBRUVICA (ibrutinib) wins Prix Galien USA 2015 Award in Best Pharmaceutical Agent category

Today, IMBRUVICA (ibrutinib) was awarded the prestigious Prix Galien USA 2015 Award in the category of Best Pharmaceutical Agent. The Prix Galien Award is considered to be the industry's highest accolade and recognizes the vital technical, scientific and clinical research skills necessary to develop medicines.

28 Oct 2015

Paxman donates scalp cooling system to Huddersfield Royal Infirmary to raise awareness of breast cancer

For UK-based Paxman – pioneers in scalp cooling – October is a poignant month. Not only is it Breast Cancer Awareness Month but it also marks fifteen years since the loss of Sue Paxman; the inspiration behind the scalp cooler.

From Paxman 28 Oct 2015

Researchers identify inherited gene variation associated with pediatric acute lymphoblastic leukemia

Researchers studying two generations of a family affected by pediatric acute lymphoblastic leukemia (ALL) have identified an inherited variation in the ETV6 gene that is associated with an increased risk of developing the disease. St. Jude Children's Research Hospital investigators led the study, which appears in the October 28 issue of the journal Lancet Oncology.

28 Oct 2015

Drug that relieves opioid-induced constipation may help some cancer patients live longer

Patients with advanced cancers who took a drug designed to relieve constipation caused by pain killers lived longer and had fewer reports of tumor progression than cancer patients who did not receive the drug, according to results presented October 27 at the 2015 meeting of the American Society of Anesthesiologists in San Diego. This is the first study in humans to associate opioid blockade with improved survival.

28 Oct 2015

Experts call for better risk profiling for GI cancers

Cancers of the gastrointestinal (GI) tract continue to exert their toll across Europe, with many diagnosed too late for effective treatment. Bowel cancer screening programmes are now underway in most European countries, but screening for other GI cancers is patchy and not necessarily well-targeted.

28 Oct 2015

Pittcon will exhibit at the Bioconference clinical diagnostics and research virtual conference

Pittcon is pleased to announce its participation in the “Clinical Diagnostics & Research” virtual conference from November 11 to 12, 2015. Clinicians, researchers, medical experts, and professionals from around the world convene for this free web-conference to learn and interact with a community of like-minded colleagues.

From Pittcon 27 Oct 2015

Entry of eleven novel therapies expected to drive NSCLC market's growth to $12.7 billion in 2024

Decision Resources Group finds that the entry of eleven novel therapies into the non-small-cell lung cancer (NSCLC) market will drive the market's growth from $5.4 billion in 2014 to $12.7 billion in 2024.

27 Oct 2015

ISIBELa joint research project aims to improve cancer therapy

Some individuals experience cancer recurrence when they enter adolescence or adulthood after they have been successfully treated for cancer in childhood while others don't. But why is this? This is the core question being considered in a research project directed by the University Medical Center of Johannes Gutenberg University Mainz.

27 Oct 2015

Galil Medical signs agreement to acquire 100% of Perseon

Galil Medical, the global leader in interventional oncology cryoablation technology, announced today it has entered into an agreement to acquire 100% of Perseon Corporation, a publicly-traded company and a leader in the field of microwave ablation, in an all cash transaction valued at $10.6M. The resulting combined company will be privately owned.

27 Oct 2015

Experts reveal link between excess body weight and colorectal cancer risk

Experts speaking at the 23rd United European Gastroenterology Week (UEG Week 2015) in Barcelona, Spain today revealed compelling evidence of the link between excess body weight and risk of colorectal cancer (CRC). John Mathers, Professor of Human Nutrition from the Institute of Cellular Medicine at Newcastle University in the UK presented data showing an overall increase of 18% in relative risk of CRC per 5 unit increase in BMI.

27 Oct 2015

Research focuses on understanding racial, ethnic disparities in colon cancer outcomes

Blase Polite, MD, has expertise in the treatment of gastrointestinal malignancies, with a particular focus on colon, rectal, and anal cancers, and neuroendocrine (carcinoid) tumors.

27 Oct 2015

New drug combination may be effective against malignant melanoma

A team of Massachusetts General Hospital investigators has discovered a new combination of drugs that may be effective against one of the deadliest cancers, malignant melanoma. The combination - pairing a drug targeted against mutations in the BRAF gene with a second drug that targets another important signaling pathway - was discovered through one of the largest screens of cancer drug combinations conducted to date.

27 Oct 2015

New approaches to treating lung cancer patients in New Mexico

This year, more than 158,000 Americans are expected to die from lung cancer. That's a staggering number: it's more than all the deaths expected from breast, prostate, colon, rectum, bladder and skin cancers combined.

26 Oct 2015

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

The U.S. Food and Drug Administration today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic).

24 Oct 2015

Oncology News and Research

Further Reading

Halozyme Therapeutics announces initiation of rivipansel Phase 1 clinical trial

UNM CCC biostatisticians help scientists conduct research on cancer

Breastfeeding associated with lower risk of developing hormone-receptor negative breast cancer

Franziska Michor named recipient of NYSCF - Robertson Stem Cell Prize

Oncolytic (cancer-killing) viral therapy approved in the U.S. for use against late-stage melanoma

Yervoy approved for patients at high risk of developing recurrence of melanoma after surgery

IMBRUVICA (ibrutinib) wins Prix Galien USA 2015 Award in Best Pharmaceutical Agent category

Paxman donates scalp cooling system to Huddersfield Royal Infirmary to raise awareness of breast cancer

Researchers identify inherited gene variation associated with pediatric acute lymphoblastic leukemia

Drug that relieves opioid-induced constipation may help some cancer patients live longer

Experts call for better risk profiling for GI cancers

Pittcon will exhibit at the Bioconference clinical diagnostics and research virtual conference

Entry of eleven novel therapies expected to drive NSCLC market's growth to $12.7 billion in 2024

ISIBELa joint research project aims to improve cancer therapy

Galil Medical signs agreement to acquire 100% of Perseon

Experts reveal link between excess body weight and colorectal cancer risk

Research focuses on understanding racial, ethnic disparities in colon cancer outcomes

New drug combination may be effective against malignant melanoma

New approaches to treating lung cancer patients in New Mexico

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

Industry Focus eBook - Oncology (3rd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News